FIGURE

Fig. 4

ID

ZDB-FIG-240401-8

Publication

Watchon et al., 2024 - Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Removal of high molecular weight (HMW) ataxin-3 by sodium butyrate is mediated by autophagy. (A) Western blots were performed on protein lysates of SH-SY5Y cells stably expressing ataxin-3-84Q treated with sodium butyrate (SB, 3 mM) and/or 3MA (5 mM) for 72 h and probed for ataxin-3 and LC3B. (B) Quantification of HMW ataxin-3 indicated that SB treatment reduced the amount of HMW ataxin-3, compared to vehicle treatment (p = .0070), and addition of 3MA treatment alone or as a co-treatment prevented the removal of the HMW ataxin-3 (p = .0086 and p = .0079, respectively, n = 6). (C) Quantification of the ataxin-3 monomeric species increased with 3MA treatment compared to the vehicle control (p = .0036). SB+3MA co-treatment further increased ataxin-3 levels compared to vehicle, SB treatment alone, and 3MA treatment alone (p < .0001, p < .0001, and p = .0214, respectively, n = 6). (D) Quantification of the LC3II/LC3I ratio revealed an increased ratio with SB treatment (p = 0002) and the addition of 3MA alone or SB+3MA co-treatment prevented this decrease in LC3II/LC3I (p = .0176 and p = .0098, respectively; n = 6–7). Data represent mean ± SEM. Statistical analysis performed was a two-way ANOVA followed by a Tukey post hoc analysis. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ FASEB J.